| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Head of R& D and CMO | Chief Medical Officer | Chief Medical Officer
2 companies
Douglas Kerr is Chief Medical Officer at GBIO, with reported holdings spanning 2 companies. Douglas Kerr's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.1M at current prices.
Our model assigns Douglas Kerr a middling insider score of 52/100, based on 10 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -9.7%.
Douglas Kerr's largest disclosed position is in DYN as Head of R& D and CMO, worth about $3.1M. The DYN filings lean toward selling, a net 17,936 shares.
Douglas Kerr has 30 Form 4 filings on record from January 2021 to October 2026, across 2 companies: Head of R & D and CMO at Dyne Therapeutics (DYN), 2024–2026; Chief Medical Officer at Generation Bio (GBIO), 2021–2024.
The 64 reported transactions were 27 open-market sales, 14 option exercises, 10 option or other derivative awards and 9 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 14 sales worth about $1.9M.
The largest open-market sale was 14,072 shares of GBIO at an average $30.09 on April 5, 2021, about $423K. Twelve months later GBIO was down 71%.
All 9 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 5,035 | $22.95 | $115,545.95 | -3.0% | - | - | |
| Aug 13, 2026 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 1,556 | $26.28 | $40,891.68 | -0.9% | - | - | |
| Jun 16, 2026 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 887 | $18.33 | $16,258.71 | -0.5% | +2.5% | - | |
| May 13, 2026 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 1,564 | $18.36 | $28,715.04 | -0.9% | +44.8% | - | |
| Mar 5, 2026 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 904 | $14.90 | $13,469.60 | -0.5% | +18.4% | - | |
| Dec 5, 2025 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 880 | $20.72 | $18,233.60 | -1.0% | -25.0% | - | |
| Sep 5, 2025 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 4,425 | $13.30 | $58,841.97 | -4.8% | +45.2% | +70.7% | |
| Jun 5, 2025 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 1,342 | $13.35 | $17,915.70 | -1.4% | -3.6% | +21.8% | |
| Mar 5, 2025 | DYN Dyne Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 1,343 | $11.83 | $15,887.69 | -1.4% | +8.9% | +24.8% | |
| Jul 8, 2021 | GBIO Generation Bio Co. | Chief Medical Officer | Sale+OE | 3,518 | $25.20 | $88,670.42 | -1.1% | -8.9% | -70.9% |